RxDoctor Payments Data

Jeffrey Sirota, MD

Nephrology · Denver, CONPI 1396882650

Payments from drug & device makers

$393in general payments, 2019–2025

Across 14 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$110
  • Amgen$90
  • Novartis$69
  • Otsuka America Pharmaceutical, Inc.$29
  • Calliditas Therapeutics US Inc.$22
  • Lilly USA, LLC$22
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$393 in reported general payments places this provider in the 30th percentile of 152 nephrology providers in Colorado.

See all nephrology providers in Colorado

Medicare billing

Part B allowed, 2024
$106,472
Medicare patients
258
Services billed
1,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate48$55,616
FarxigaDapagliflozin Propanediol22$30,852
JardianceEmpagliflozin17$15,688
VeltassaPatiromer Calcium Sorbitex14$14,027
Potassium Citrate ErPotassium Citrate32$3,983
Calcitriol102$2,629
Sevelamer Carbonate14$2,432
Calcium Acetate23$1,634
Midodrine Hcl22$1,359
Amlodipine Besylate121$989
Furosemide70$744
Hydralazine Hcl55$717
Potassium Chloride32$712
Spironolactone24$679
Losartan Potassium39$408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$16$86,46870 claims
Boehringer IngelheimJardiance$110$15,68817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 152 nephrology providers in Colorado.

Other nephrology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →